Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaru Murai

Showing results (11-20 of 115) with videos related to

Pageof 12
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 31, 2002
[What is the impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma?]Mototsugu Oya, Masaru Murai
Nihon Rinsho. Japanese Journal of Clinical Medicine|February 26, 2003
[Prostate specific membrane antigen (PSMA) as a role of tumor marker]Shiro Saito, Yutaka Horiguchi, Masaru Murai
Kidney International|February 19, 2002
STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769PAkio Horiguchi, Mototsugu Oya, Ken Marumo, et al.
Urology|March 27, 2007
Carcinoma in situ developing in an ileal neobladderHiroki Ide, Eiji Kikuchi, Kazunobu Shinoda, et al.
Journal of Endourology|September 27, 2006
Endocytoscopy: novel endoscopic imaging technology for in-situ observation of bladder cancer cellsTakashi Ohigashi, Norihide Kozakai, Ryuichi Mizuno, et al.
Expert Review of Anticancer Therapy|December 23, 2003
Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cellsYutaka Horiguchi, Kenji Kuroda, Jun Nakashima, et al.
Japanese Journal of Clinical Oncology|October 24, 2007
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinomaHideyuki Akaza, Taiji Tsukamoto, Masaru Murai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Increased activation of CCAAT/enhancer binding protein-beta correlates with the invasiveness of renal cell carcinomaMototsugu Oya, Akio Horiguchi, Ryuichi Mizuno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancerMichio Kosugi, Akira Miyajima, Eiji Kikuchi, et al.
Cancer Investigation|August 29, 2002
Bcl-2 and androgen receptor gene expression in androgen-independent subclone derived from mouse androgen-dependent cellsTakashi Ohigashi, Munehisa Ueno, Shoichi Nonaka, et al.
Pageof 12

Showing results (11-20 of 115) with videos related to

Sort By:
Pageof 12
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 31, 2002
[What is the impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma?]Mototsugu Oya, Masaru Murai
Nihon Rinsho. Japanese Journal of Clinical Medicine|February 26, 2003
[Prostate specific membrane antigen (PSMA) as a role of tumor marker]Shiro Saito, Yutaka Horiguchi, Masaru Murai
Kidney International|February 19, 2002
STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769PAkio Horiguchi, Mototsugu Oya, Ken Marumo, et al.
Urology|March 27, 2007
Carcinoma in situ developing in an ileal neobladderHiroki Ide, Eiji Kikuchi, Kazunobu Shinoda, et al.
Journal of Endourology|September 27, 2006
Endocytoscopy: novel endoscopic imaging technology for in-situ observation of bladder cancer cellsTakashi Ohigashi, Norihide Kozakai, Ryuichi Mizuno, et al.
Expert Review of Anticancer Therapy|December 23, 2003
Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cellsYutaka Horiguchi, Kenji Kuroda, Jun Nakashima, et al.
Japanese Journal of Clinical Oncology|October 24, 2007
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinomaHideyuki Akaza, Taiji Tsukamoto, Masaru Murai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Increased activation of CCAAT/enhancer binding protein-beta correlates with the invasiveness of renal cell carcinomaMototsugu Oya, Akio Horiguchi, Ryuichi Mizuno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancerMichio Kosugi, Akira Miyajima, Eiji Kikuchi, et al.
Cancer Investigation|August 29, 2002
Bcl-2 and androgen receptor gene expression in androgen-independent subclone derived from mouse androgen-dependent cellsTakashi Ohigashi, Munehisa Ueno, Shoichi Nonaka, et al.
Pageof 12